Philip C Mack
Overview
Explore the profile of Philip C Mack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
4185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karim N, Rabea A, Mack P, Subramanian J, Khalil E, Sherif M, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100776.
PMID: 39790369
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting of the Thoracic Oncology Multidisciplinary Faculty, organized by...
2.
Somisetty M, Mack P, Hsu C, Huang Y, Gomez J, Rodilla A, et al.
Clin Lung Cancer
. 2024 Aug;
25(7):612-618.
PMID: 39122606
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be spread by individuals unaware they are infected. Such dissemination has heightened ramifications in cancer patients, who may need to visit...
3.
Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, et al.
J Thorac Oncol
. 2024 Aug;
19(12):1618-1629.
PMID: 39111731
Introduction: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung...
4.
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer
Mack P, Hsu C, Rodilla A, Gomez J, Cagan J, Huang Y, et al.
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066351
In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging,...
5.
Desai A, Vazquez T, Arce K, Corassa M, Mack P, Gray J, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473302
Circulating tumor DNA (ctDNA) offers a new paradigm in optimizing treatment strategies for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Its potential spans early-stage disease, influencing...
6.
Lin D, Huang R, Ladas I, Keller R, Patel N, Lakis S, et al.
Front Oncol
. 2024 Mar;
14:1328512.
PMID: 38444675
Background: While many molecular assays can detect mutations at low tumor purity and variant allele frequencies, complex biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and genomic loss...
7.
Mack P, Keller-Evans R, Li G, Lofgren K, Schrock A, Trabucco S, et al.
Oncologist
. 2024 Feb;
29(8):e984-e996.
PMID: 38401173
Background: Genomic fusions are potent oncogenic drivers across cancer types and many are targetable. We demonstrate the clinical performance of DNA-based comprehensive genomic profiling (CGP) for detecting targetable fusions. Materials...
8.
Rodilla A, Valanparambil R, Mack P, Hsu C, Cagan J, Tavolacci S, et al.
Cancer Cell
. 2023 Oct;
41(11):1838-1840.
PMID: 37863065
Patients diagnosed with lung cancer (LC) exhibit increased susceptibility to SARS-CoV-2 infection. Rodilla et al. monitor the levels of plasma anti-nucleocapsid antibodies within a cohort of fully vaccinated LC patients...
9.
Rodilla A, Tavolacci S, Cagan J, Shah T, Mittan S, Mack P, et al.
Vaccines (Basel)
. 2023 May;
11(5).
PMID: 37243073
In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to...
10.
Gadgeel S, Miao J, Riess J, Moon J, Mack P, Gerstner G, et al.
Clin Cancer Res
. 2023 May;
29(18):3641-3649.
PMID: 37233987
Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and comutations. Our hypothesis was that docetaxel and trametinib would improve activity in KRAS+ NSCLC...